Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
| Autor: | David Chardin, Marius Ilie, Renaud Schiappa, Michel Poudenx, Jonathan Benzaquen, Olivier Humbert, Aurélie Sciazza, Caroline Bailleux, Nicolas Martin, M. Paquet, Jacques Darcourt, Josiane Otto |
|---|---|
| Přispěvatelé: | Université Côte d'Azur (UCA), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), UMR E4320 (TIRO-MATOs), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA), ANR-19-P3IA-0002,3IA@cote d'azur,3IA Côte d'Azur(2019), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Immunology 03 medical and health sciences 0302 clinical medicine biomarkers tumor Internal medicine Carcinoma Non-Small-Cell Lung parasitic diseases Immunotherapy Biomarkers medicine Immunology and Allergy Humans In patient Prognostic biomarker Prospective Studies Lung cancer Prospective cohort study Immune Checkpoint Inhibitors ComputingMilieux_MISCELLANEOUS Aged Pharmacology Aged 80 and over business.industry Immunotherapy Metabolic tumor volume Middle Aged medicine.disease 3. Good health Discontinuation 030104 developmental biology 030220 oncology & carcinogenesis tumor biomarkers Molecular Medicine Female Non small cell immunotherapy business [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Zdroj: | Journal for Immunotherapy of Cancer Journal for Immunotherapy of Cancer, 2020, 8 (2), pp.e000645. ⟨10.1136/jitc-2020-000645⟩ Journal for Immunotherapy of Cancer, BMJ Publishing Group 2020, 8 (2), pp.e000645. ⟨10.1136/jitc-2020-000645⟩ |
| ISSN: | 2051-1426 |
| DOI: | 10.1136/jitc-2020-000645⟩ |
| Popis: | BackgroundReliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic and predictive values of different baseline metabolic parameters, including metabolic tumor volume (MTV), from 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT) scans in patients with NSCLC treated with PD1 inhibitors.MethodsMaximum and peak standardized uptake values, MTV and total lesion glycolysis (TLG), as well as clinical and biological parameters, were recorded in 75 prospectively included patients with NSCLC treated with PD1 inhibitors. Associations between these parameters and overall survival (OS) were evaluated as well as their accuracy to predict early treatment discontinuation (ETD).ResultsA high MTV and a high TLG were significantly associated with a lower OS (p3) was 10.5 months (95% CI: 6.2 to upper limit: unreached), while the median OS in patients with MTV below the median was not reached. Patients with no prior chemotherapy had a poorer OS than patients who had received prior systemic treatment (p=0.04). MTV and TLG could reliably predict ETD (area under the receiver operating characteristic curve=0.76, 95% CI: 0.65 to 0.87 and 0.72, 95% CI: 0.62 to 0.84, respectively).ConclusionMTV is a strong prognostic and predictive factor in patients with NSCLC treated with PD1 inhibitors and can be easily determined from routine 18F-FDG PET/CT scans. MTV, could help to personalize immunotherapy and be used to stratify patients in future clinical studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|